Perinatal infections and fetal/neonatal brain injury

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 2, 2008, Pages 120-124

  Ledger, William J ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Obstetrics and Gynecology ^*  (United States)

Author keywords

Chemotherapeutic agents; Chorioamnionitis; Cytomegalovirus; Group B Streptococcus; Rubella; Toxoplasmosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CYTOMEGALOVIRUS VACCINE; FOLINIC ACID; MEASLES MUMPS RUBELLA VACCINE; PYRIMETHAMINE; SPIRAMYCIN; STEROID; STREPTOCOCCUS VACCINE; SULFADIAZINE;

ANTIBIOTIC PROPHYLAXIS; BRAIN INJURY; CHORIOAMNIONITIS; COST OF ILLNESS; CYTOMEGALOVIRUS; ECONOMIC ASPECT; FETUS; FETUS DISEASE; HUMAN; IMMUNIZATION; MASS SCREENING; MORBIDITY; NEWBORN; NEWBORN DISEASE; NEWBORN MORBIDITY; NEWBORN MORTALITY; PERINATAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RUBELLA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; TOXOPLASMOSIS; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BRAIN; BRAIN DISEASES; CHORIOAMNIONITIS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RUBELLA; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; TOXOPLASMOSIS;

EID: 41849146779     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f734db     Document Type: Review

References (25)

1. Plotkin SA. The history of Rubella and Rubella vaccination leading to elimination. Clin Inf Dis 2006; 43:S164-S168.
2. Reef SE, Cochi SL. The evidence for the elimination of Rubella and congenital Rubella syndrome in the United States: a public health achievement. Clin Inf Dis 2006; 43:S123-S125.
3. Centers for Disease Control. Prevention of perinatal Group B streptococcal disease: a public health perspective. Morb Mortal Weekly Rep 1996; 145(RR-7):1-24.
4. Ledger WJ. CDC guidelines for the prevention of perinatal Group B streptococcal disease: are they appropriate? Inf Dis Clin Prac 1998; 7:188-193.
5. Centers for Disease Control. Perinatal Group B streptococcal disease after universal screening recommendation - United States, 2003-2005. Morb Mortal Weekly Rep 2007; 56:701-706. This is a detailed view of recent results with Group B Streptococcus antibiotic prophylaxis.
6. Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogen causing early onset sepsis in very low birth weigh infants. N Engl J Med 2002; 347:240-247.
7. Mayor-Lynn K, Gonzalez-Quintero VH, O'Sullivan MJ, et al. Comparison of early onset neonatal sepsis caused by Escherichia coli and Group B streptococcus. Am J Obstet Gynecol 2005; 192:1437-1439.
8. Staras SAS, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43:1143-1151.
9. Ogawa H, Suzutani T, Baba Y, et al. Etiology of severe sensorineural hearing loss children: independent impact of congenital cytomegalovirus infection and GJB2 mutations. J Infect Dis 2007; 195:782-788.
10. ACOG Practice Bulletin. Perinatal viral and parasitic infection. Clin Management Guidelines 2000; 20:1-13.
11. Adler SP, Finney JW, Manganello AM, et al. Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect Dis J 1996; 15:240-246.
12. La Torne R, Nigro G, Mazzocco M, et al. Placental enlargement in women with primary maternal cytomegalovirus is associated with fetal and neonatal disease. Clin Infect Dis 2006; 43:994-1000.
13. Guernia NG, Hsu H-W, Messner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med 1994; 330:1858-1863.
14. Koppe JG, Loewer-Sieger DH, de Roever-Bonnot H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1986; 1:254-256.
15. Centers for Disease Control. US PHS/1DSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. A summary. Morb Mortal Weekly Rep 1995; 44:1-34.
16. Foulon W. Congenital toxoplasmosis: is screening desirable? Scand J Infect Dis Suppl 1992; 84:11-17.
17. Levine EM. Risk factors for toxoplasmosis gondii infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening. Am J Obstet Gynecol 2006; 194:589.
18. Garry DJ, Elimian A, Wiencek V, et al. Commercial laboratory IgM testing for toxoplasmosis gondii in pregnancy: a 20-year experience. Infect Dis Obstet Gynecol 2005; 13:151-153.
19. Boyer KM, Holfels E, Roizen N, et al. Risk factors for toxoplasmosis gondii infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening. Am J Obstet Gynecol 2005; 192:564-571.
20. Romand S, Wallon M, Franck J, et al. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol 2001; 97:296-300.
21. McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: The National Collaborative Chicago Board congenital toxoplasmosis study. Clin Infect Dis 2006; 42:1383-1394.
22. Koh KS, Chan FH, Nonfaved AH, et al. The changing perinatal and maternal outcome in chorioamnionitis. Obstet Gynecol 1979; 53:730-734.
23. Grethner JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal brith weight. JAMA 1997; 278:207-211.
24. Gomez R, Romero R, Ghezzi F, et al. The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998; 179:194-202.
25. Kent A, Lomas F, Hurrion E, et al. Antenatal steroids may reduce adverse neurological outcome following chorioamnionitis: neurodevelopmental outcome and chorioamnionitis in premature infants. J Paediatr Child Health 2005; 41:186-190.